The Symphony Capital team brings more than two decades of strategic, financial, clinical and regulatory experience within the biopharmaceutical industry to our portfolio companies’ pipelines. Our experience in financing and advising many of the world’s leading biotechnology companies extends back to the earliest days of the industry. When companies collaborate with Symphony, they are able to maintain substantial flexibility in downstream commercialization options and avoid premature out-licensing that ultimately erodes shareholder value. In Symphony, biopharmaceutical companies have a trusted, collaborative partner to whom they can transfer substantial clinical development risk.
Symphony brings world-class clinical design and management capabilities to enable biopharmaceutical companies to maximize the development opportunity of each pipeline program. Our exclusive alliance with RRD International provides an unparalleled breadth and depth of clinical development resources to a biopharmaceutical company’s pipeline. Through their careers at FDA, leading biopharmaceutical companies and CROs, RRD’s executives have decades of clinical development expertise. RRD manages and designs global and domestic clinical development programs in collaboration with biopharmaceutical companies with an eye towards regulatory approval. They manage all aspects of biopharmaceutical product development including clinical, preclinical, regulatory/quality systems and manufacturing. RRD’s far-reaching networks of clinical and technical experts allow them to have broad expertise across all therapeutic areas and classes of drugs.